Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Johnson & Johnson gets green light for lung cancer combination treatment

Published 08/20/2024, 07:49 AM
Updated 08/20/2024, 07:52 AM
© Reuters.  Johnson & Johnson gets green light for lung cancer combination treatment
JNJ
-

Johnson & Johnson (NYSE:JNJ) announced Tuesday that it has received U.S. Food and Drug Administration (FDA) approval for a combination treatment of RYBREVANT and LAZCLUZE for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations.

According to the company, it marks a breakthrough in lung cancer treatment, as it is the first and only multitargeted, chemotherapy-free combination regimen approved for this patient population.

The combination therapy is said to have demonstrated superior efficacy in reducing the risk of disease progression or death compared to the current standard of care, osimertinib, in the Phase 3 MARIPOSA study.

Lung cancer remains a leading cause of cancer mortality worldwide, with NSCLC accounting for the majority of cases.

"Today's FDA approval of chemotherapy-free RYBREVANT plus LAZCLUZE in the first line is an incredible step towards our goal of altering the trajectory of lung cancer and reducing the impact of the world's leading cause of cancer mortality," said John Reed, Executive Vice President of Innovative Medicine R&D at Johnson & Johnson

JNJ said the combination therapy targets the EGFR mutations directly and has shown promising results in terms of progression-free survival and duration of response.

They added that the safety profile of RYBREVANT plus LAZCLUZE was consistent with the profiles of the individual treatments.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.